WPRT vs KLRS Comparison

Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three operating segments; the Original Equipment Manufacturers segment-design, manufacture, and sell alternative fuel systems, components and electronics, and related engineering services, to OEMs that serve light-duty, medium-duty, and heavy-duty customers, the Independent Aftermarket segment includes IAM products, conversion kits, and components allow for the conversion of vehicles after being sold to the end-user through a network of dealers and installers, and Corporate includes public company activities, corporate oversight, financing and capital allocation.

Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.